Kura Oncology (KURA) Shares Could Go Higher After AML Drug Approval Says Citizens
Tweet Send to a Friend
Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA). The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
